Imunon Rises As Ovarian Cancer Drug Prolongs Survival In Mid: stage study

Imunon

25/03/2026 12:27

** Shares of biotech firm IMUNON IMNN.O rise 6.8% to $3.10 premarket

** Co says its experimental drug IMNN-001 helped patients with advanced ovarian cancer, a deadly cancer that is often diagnosed late and frequently returns after treatment

** Final data from a mid‑stage study shows median overall survival of 45.1 months with IMNN-001 plus chemotherapy vs 30.4 months with chemotherapy alone, co says

** Says survival rose to 65.6 months when IMNN-001 was used with chemo and PARP inhibitors, drugs that stop cancer cells from repairing DNA

** IMNN-001 is given directly into the abdomen to stimulate the immune system and showed a favourable safety profile, co says

** Says enrolment in a late‑stage trial is ahead of schedule, targeting about 500 patients

** Shares down ~69% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))